Bharat Biotech’s Covaxin: Clinical trials for third dose allowed

The firm presented amendments in the approved Phase 2 clinical trial protocol for administration of booster dose after six months after the second dose

86
Laboratory
Picture: Pixabay

The expert panel of DCGI has permitted Bharat Biotech to give a third dose of Covaxin to a few volunteers in its clinical trials of the C-19 vaccine, sources said.

Bharat Biotech presented amendments to the subject expert committee of the Drugs Controller General of India (DCGI) in the approved Phase 2 clinical trial protocol for administration of booster dose six months after second dose.


To read more about Bharat Biotech, click here


The firm presented amendments in the approved Phase 2 clinical trial protocol for administration of booster dose after six months after the second dose. After detailed deliberation, the committee recommended that the firm should conduct the booster dose study only in 6 mcg cohort and also should follow up the subjects at least for six months after the third dose,” the SEC said.

Opinion People meeting
Picture: Pixabay

Further, Bharat Biotech was asked to present the details of the primary and secondary objectives and various assessments to be carried out in the subjects.

“Accordingly, firm (Bharat Biotech) should submit the revised clinical trial protocol for evaluation,” the SEC said in the meeting that took place on March 23.


Also read:

Why some cancer drugs may be ineffective

High Court: Set up separate FSL for testing drugs

Appeal to DCGI to implement DCC guidelines on NSQ drugs: Pharma…

Niyukti 2021: The Job Fest on 10th April (Pharmacy job opportunities)…

How to start Jan Aushadhi Store: Procedure


In the meeting, Bharat Biotech presented amendments in the approved Phase 3 clinical trial protocol for unblinding of subjects on placebo and addition of another cohort in Brazil which the SEC recommended.

“After detailed deliberation, the committee recommended that the firm may unblind the participants of age group of more than 45 years and offer to administer the vaccine free of cost as and when they become eligible for the vaccine in the national program,” the SEC said.

Further, the SEC recommended that the firm should submit a detailed revised clinical trial protocol for inclusion of cohorts from Brazil along with the revised statistical calculation for assessing the efficacy of the vaccine.


Enter your email address:

Delivered by FeedBurner

Latest updates

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading